Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus

Table 3

Logistic regression analysis for the improvement of GIR (>0.5 mg/min/kg) in patients with uncontrolled type 2 DM.

Baseline variable	Univariate regression			Multivariate regression using forced inclusion model
	OR	95% CI		OR	95% CI
Age (per year)	0.997	0.932 to 1.068	0.94		—
Gender (male)	1.805	0.377 to 8.621	0.46		—
Body mass index (per 1.0)	1.241	0.925 to 1.665	0.15	1.161	0.847 to 1.591	0.35
Hypertension (yes)	4.167	0.664 to 26.31	0.128		—
Dyslipidemia (yes)	1.835	0.432 to 7.752	0.411		—
Current smoker (yes)	0.333	0.051 to 2.179	0.251		—
Hemoglobin A1c (per 0.1; %)	1.147	0.536 to 2.455	0.724		—
Fasting plasma glucose (per 1.0; mg/dL)	0.996	0.974 to 1.019	0.752		—
Fasting blood CPR (per 1.0; ng/mL)	1.265	0.615 to 2.601	0.523		—
Duration of diabetes (per 1.0; years)	0.981	0.908 to 1.059	0.623		—
Liraglutide-therapy (yes)	5.989	1.231 to 28.57	0.024	5.076	1.024 to 25.00	0.047

OR, odds ratio; CI, confidence interval; CPR, C-peptide radioimmunoreactivity.
Hosmer-Lemeshow = 0.19 in multivariate analysis.